MedTrace Logo

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

NCT01015222 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2022-11-23

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Conditions

Interventions

DRUG

Dasatinib

Starting dose of 50 mg daily PO for 28 day cycle

DRUG

Bevacizumab

Starting dose 5 mg/kg IV Day 1 and 15

DRUG

Paclitaxel

Starting dose 40 mg/m2 IV Day 1, 8 and 15

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Filip Janku, MD,PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2021-05-27
Completion
2021-05-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01015222 on ClinicalTrials.gov